Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Key Points
Key points are not available for this paper at this time.
Abstract
Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial | Synapse